Abstract
BackgroundTargeted treatments are becoming the mainstay for many autoinflammatory diseases, including the systemic juvenile idiopathic arthritis (sJIA). Canakinumab (CAB), a fully human anti-interleukin-1β (IL-1β) antibody, has recently been shown to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have